Edgewood Management’s Royalty Pharma RPRX Stock Holding History

Edgewood Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-23,000	Closed	-$829K	–	84
2023 Q1	$829K	Hold	23,000	–	–	﹤0.01%	58
2022 Q4	$909K	Hold	23,000	–	–	﹤0.01%	53
2022 Q3	$924K	Hold	23,000	–	–	﹤0.01%	50
2022 Q2	$967K	Hold	23,000	–	–	﹤0.01%	51
2022 Q1	$896K	Hold	23,000	–	–	﹤0.01%	53
2021 Q4	$917K	Hold	23,000	–	–	﹤0.01%	56
2021 Q3	$831K	Sell	23,000 -20,000	-47%	-$777K	﹤0.01%	57
2021 Q2	$1.76M	Sell	43,000 -53,500	-55%	-$2.28M	﹤0.01%	42
2021 Q1	$4.21M	Hold	96,500	–	–	0.01%	36
2020 Q4	$4.83M	Buy	96,500 +6,500	+7%	+$276K	0.01%	34
2020 Q3	$3.79M	Buy	90,000 +20,000	+29%	+$858K	0.01%	39
2020 Q2	$3.4M	Buy	+70,000	New	+$3.46M	0.01%	38

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Edgewood Management's RPRX Position: Q2 2023 in Review

Edgewood Management sold out of Royalty Pharma (RPRX) in Q2 2023, closing a stake of 23,000 shares — an estimated $829K sold.

Edgewood Management first reported a position in RPRX in Q2 2020 and held it in 12 quarters. The position peaked at $4.83M in Q4 2020. 325 funds tracked by Wall St. Rank hold RPRX as of Q2 2023.

Edgewood Management reported no remaining Royalty Pharma position as of Q2 2023 after selling out during the quarter.
Edgewood Management sold 23,000 Royalty Pharma shares in Q2 2023, an estimated $829K.
Edgewood Management first reported a position in Royalty Pharma in Q2 2020 and held it in 12 quarters.
Edgewood Management's Royalty Pharma position peaked at $4.83M in Q4 2020.
325 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2023.

Based on Edgewood Management's 13F filing for Q2 2023, filed 11 Aug 2023.